Aldeyra Therapeutics, Inc. (ALDX) Discusses PDUFA Target Action Date Extension for Reproxalap in Dry Eye Disease Transcript
Summarize this article with:
SA Transcripts157.37K FollowersFollow5ShareSaveComment(1)Play Earnings CallPlay Earnings Call Aldeyra Therapeutics, Inc. (ALDX) Discusses PDUFA Target Action Date Extension for Reproxalap in Dry Eye Disease December 16, 2025 8:00 AM EST Company Participants Laura Nichols - Operations ManagerTodd Brady - CEO, President & Director Conference Call Participants Catherine Novack - JonesTrading Institutional Services, LLC, Research DivisionMatthew Caufield - H.C. Wainwright & Co, LLC, Research DivisionBasma Radwan Ibrahim - Leerink Partners LLC, Research DivisionThomas Shrader - BTIG, LLC, Research DivisionYale Jen - Laidlaw & Company (UK) Ltd., Research Division Presentation Operator Hello, everyone, and thank you for joining us today for the Aldeyra Therapeutics Regulatory Update Conference Call. My name is Sammy, and I'll be coordinating your call today. [Operator Instructions] I'll now hand over to your host, Laura Nichols, Associate Director of Investor Relations at Aldeyra Therapeutics to begin. Please go ahead, Laura. Laura NicholsOperations Manager Thank you, and good morning, everyone. Today, we issued a press release announcing a PDUFA target action date extension for the new drug application of reproxalap for the treatment of dry eye disease. A copy of the press release is available on the Investor and Media section of our website, www.aldeyra.com. The press release contains important information and should be read and considered in conjunction with the prepared remarks on today's call. With me today to discuss the PDUFA extension is Dr. Todd Brady, President and Chief Executive Officer of Aldeyra. This presentation contains forward-looking statements regarding Aldeyra in the investigational drug candidate, reproxalap, and Aldeyra's plans, expectations and opportunities, including regulatory activities regarding reproxalap. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Aldeyra's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements are based upon the information available to Aldeyra today